TrialJournal of cancer research and clinical oncology2025
A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer.
Jingshu Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.